A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI 61)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI 61)

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity; Overweight
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAMELLIA-TIMI; CAMELLIA-TIMI 61
  • Sponsors Eisai Inc
  • Most Recent Events

    • 22 Jun 2017 According to an Eisai Co Ltd media release, based on the interim safety analysis of this trial, an independent Data Monitoring Committee has recommended to continue this trial as planned.
    • 27 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
    • 27 Feb 2017 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top